English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Chronic immune thrombocytopenia (ITP) is an autoimmune disease characterized by immune-mediated platelet destruction and reduced platelet production caused by antiplatelet autoantibodies, leading to a marked decrease in platelet count and rarely life-threatening bleeding [1]. The main treatment purpose for chronic ITP is to maintain platelet counts sufficient to minimize bleeding risk [2]. First-line treatments for chronic ITP include corticosteroids, intravenous immunoglobulins, anti-D, and various immunosuppressive or cytotoxic drugs (e.g., vincristine, cyclophosphamide, cyclosporine A, and rituximab), with the main emphasis on preventing platelet destruction. However, first-line therapy is often ineffective and can be limited by side effects [3].

Eltrombopag: a new treatment option for chronic refractory adult immune thrombocytopenia